Evidence map›Paper›PMID 36726288›Full record

ArticleAIDS care2023

Providing HIV pre-exposure prophylaxis to men who have sex with men and transgender women in hospitals and community-led clinics in Thailand: acceptance, patterns of use, trends in risk behaviors, and HIV incidence.

Cheewanan L, Chomnad M, Nittaya P, Deondara T, Thana K, Tharee P, Supabhorn P, Patcharaporn P, Prin V, Surang J and 4 more

Abstract read
In one paragraph

Article in AIDS care, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Cheewanan LDivision of AIDS and STIs, Ministry of Public Health, Bangkok, Thailand.
Chomnad MDivision of Global HIV & Tuberculosis, U.S. Centers for Disease Control and Prevention, Nonthaburi, Thailand.
Nittaya PInstitute of HIV Research and Innovation, Bangkok, Thailand.
Deondara TInstitute of HIV Research and Innovation, Bangkok, Thailand.
Thana KFaculty of Medicine, Thammasat University, Pathumthani, Thailand.
Tharee PDepartment of Medical Services, Ministry of Public Health, Lerdsin hospital, Bangkok, Thailand.
Supabhorn PInstitute of HIV Research and Innovation, Bangkok, Thailand.
Patcharaporn PDivision of AIDS and STIs, Ministry of Public Health, Bangkok, Thailand.
Prin VDivision of Global HIV & Tuberculosis, U.S. Centers for Disease Control and Prevention, Nonthaburi, Thailand.
Surang JService Workers in Group Foundation (SWING), Bangkok, Thailand.
Danai LRainbow Sky Association of Thailand, Bangkok, Thailand.
Thitiyanun NSisters Foundation, Pattaya, Thailand.
Nuchapong JDivision of Global HIV & Tuberculosis, U.S. Centers for Disease Control and Prevention, Nonthaburi, Thailand.
Michael MDivision of Global HIV & Tuberculosis, U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA.

Funding

CGH CDC HHS U2G GH000616Intramural CDC HHS CC999999PEPFAR
6 · The paper itself

Abstract

From May 2015 to June 2018, we conducted a PrEP demonstration project at two hospitals and four community-led clinics in Bangkok and Pattaya. HIV-negative, MSM and TGW aged ≥18 years old, reporting sex without a condom, were offered daily PrEP. Participants received HIV testing and completed a computer-based questionnaire at enrollment, 6 and 12 months. We collected self-reported PrEP adherence at months 1, 3, 6, 9, and 12. We used logistic regression to determine factors associated with the decision to take PrEP and calculated HIV incidence among baseline HIV-negative participants. Of 803 participants enrolled, 349 (43.5%) started PrEP. Participants were more likely to start PrEP if they were sex workers, had moderate or high self-perceived risk of HIV, or a high PrEP-knowledge score. Participants used PrEP for a median of 6.1 months. Reported condom use increased and the number of sex partners decreased during follow-up regardless of PrEP use. Six participants not-taking PrEP acquired HIV (HIV incidence 2.2 per 100 person-years), and five taking PrEP acquired HIV (HIV incidence 2.1 per 100 person-years). All five reported taking <4 pills the weeks before study visits.

Indexed as

Anti-HIV AgentsHIV-1HIV InfectionsHIV SeropositivityPre-Exposure ProphylaxisSexual and Gender MinoritiesTransgender PersonsAdolescentAdultFemaleHomosexuality, MaleHospitalsHumansIncidenceMaleRisk-TakingAnti-HIV AgentsHIV incidenceMSMPre-exposure prophylaxisThailandtransgender women

Identifiers

PMID36726288
PMCPMC10121879

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.